These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 25672738)

  • 21. [Frontotemporal dementia: tau mutations, deposition, and molecular mechanisms of neuronal cell death].
    Hasegawa M
    Rinsho Shinkeigaku; 2004 Nov; 44(11):879-81. PubMed ID: 15651320
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cognitive enhancers (Nootropics). Part 3: drugs interacting with targets other than receptors or enzymes. Disease-modifying drugs. Update 2014.
    Froestl W; Pfeifer A; Muhs A
    J Alzheimers Dis; 2014; 42(4):1079-149. PubMed ID: 25061058
    [TBL] [Abstract][Full Text] [Related]  

  • 23. From understanding synaptic plasticity to the development of cognitive enhancers.
    Cheung ZH; Ip NY
    Int J Neuropsychopharmacol; 2011 Oct; 14(9):1247-56. PubMed ID: 21208502
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Abnormal hyperphosphorylation of tau: sites, regulation, and molecular mechanism of neurofibrillary degeneration.
    Wang JZ; Xia YY; Grundke-Iqbal I; Iqbal K
    J Alzheimers Dis; 2013; 33 Suppl 1():S123-39. PubMed ID: 22710920
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Increase in the relative expression of tau with four microtubule binding repeat regions in frontotemporal lobar degeneration and progressive supranuclear palsy brains.
    Ingelsson M; Ramasamy K; Russ C; Freeman SH; Orne J; Raju S; Matsui T; Growdon JH; Frosch MP; Ghetti B; Brown RH; Irizarry MC; Hyman BT
    Acta Neuropathol; 2007 Nov; 114(5):471-9. PubMed ID: 17721707
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tau-directed approaches for the treatment of Alzheimer's disease: focus on leuco-methylthioninium.
    Seripa D; Solfrizzi V; Imbimbo BP; Daniele A; Santamato A; Lozupone M; Zuliani G; Greco A; Logroscino G; Panza F
    Expert Rev Neurother; 2016; 16(3):259-77. PubMed ID: 26822031
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Drug development in dementia.
    Cunningham EL; Passmore AP
    Maturitas; 2013 Nov; 76(3):260-6. PubMed ID: 23707728
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Novel insights for the treatment of Alzheimer's disease.
    Kurz A; Perneczky R
    Prog Neuropsychopharmacol Biol Psychiatry; 2011 Mar; 35(2):373-9. PubMed ID: 20655969
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacotherapy for Frontotemporal Dementia.
    Khoury R; Liu Y; Sheheryar Q; Grossberg GT
    CNS Drugs; 2021 Apr; 35(4):425-438. PubMed ID: 33840052
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Development of new drugs for Alzheimer's disease].
    Tabira T
    Brain Nerve; 2010 Jul; 62(7):787-96. PubMed ID: 20675883
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Frontotemporal dementia with tau pathology.
    Gasparini L; Terni B; Spillantini MG
    Neurodegener Dis; 2007; 4(2-3):236-53. PubMed ID: 17596718
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Drug development for overcoming dementia in Japan].
    Nakamura H
    Rinsho Shinkeigaku; 2014; 54(12):1181-3. PubMed ID: 25672739
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antiepileptic Drugs Modulate Alzheimer-Related Tau Aggregation in a Neuronal Activity-Independent Manner.
    Ito Y; Takeda S; Moroi S; Nakajima T; Oyama A; Miki K; Sugihara N; Takami Y; Takeya Y; Shimamura M; Rakugi H; Morishita R
    Dement Geriatr Cogn Disord; 2023; 52(2):108-116. PubMed ID: 36878194
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dementia experts are optimistic despite decline in hope for effective drugs.
    Hawkes N
    BMJ; 2013 Jul; 347():f4265. PubMed ID: 23818576
    [No Abstract]   [Full Text] [Related]  

  • 35. Nefiracetam. DM 9384, DZL 221, Translon.
    Drugs R D; 1999 Aug; 2(2):137-41. PubMed ID: 10820661
    [No Abstract]   [Full Text] [Related]  

  • 36. NICE and anti-dementia drugs: a triumph of health economics over clinical wisdom?
    O'Brien JT
    Lancet Neurol; 2006 Dec; 5(12):994-6. PubMed ID: 17110274
    [No Abstract]   [Full Text] [Related]  

  • 37. [Development of anti-dementia drugs related to neurotrophic factors].
    Obara Y
    Yakugaku Zasshi; 2006 Sep; 126(9):747-55. PubMed ID: 16946588
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The anti-dementia drug candidate, (-)-clausenamide, improves memory impairment through its multi-target effect.
    Chu S; Liu S; Duan W; Cheng Y; Jiang X; Zhu C; Tang K; Wang R; Xu L; Wang X; Yu X; Wu K; Wang Y; Wang M; Huang H; Zhang J
    Pharmacol Ther; 2016 Jun; 162():179-87. PubMed ID: 26812265
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Neuropathobiology of senile dementia and mechanism of action of nootropic drugs.
    Benesová O
    Drugs Aging; 1994 Apr; 4(4):285-303. PubMed ID: 8019052
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Identification of an ERK Inhibitor as a Therapeutic Drug Against Tau Aggregation in a New Cell-Based Assay.
    Siano G; Caiazza MC; Ollà I; Varisco M; Madaro G; Quercioli V; Calvello M; Cattaneo A; Di Primio C
    Front Cell Neurosci; 2019; 13():386. PubMed ID: 31496937
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.